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Abstract
The Protein Data Bank (PDB) today contains more than 153,000 entries
with the 3-dimensional structures of biological macromolecules. Using the
rich resources of this repository, it is possible identifying subsets with spe-
cific, interesting properties for different applications. Our research group pre-
pared an automatically updated list of amyloid- and probably amyloidogenic
molecules, the PDB Amyloid collection, which is freely available at the address
http://pitgroup.org/amyloid. This resource applies exclusively the geomet-
ric properties of the steric structures for identifying amyloids. In the present
contribution, we analyze the starting (i.e., prefix) subsequences of the character-
istic, parallel beta-sheets of the structures in the PDB Amyloid collection, and
identify further appearances of these length-5 prefix subsequences in the whole
PDB data set. We have identified this way numerous proteins, whose normal
or irregular functions involve amyloid formation, structural misfolding, or anti-
coagulant properties, simply by containing these prefixes: including the T-cell
receptor (TCR), bound with the major histocompatibility complexes MHC-1
and MHC-2; the p53 tumor suppressor protein; a mycobacterial RNA poly-
merase transcription initialization complex; the human bridging integrator pro-
tein BIN-1; and the tick anti-coagulant peptide TAP.
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Introduction
Amyloids are misfolded protein aggregates, which are present in numerous
biological organisms as structural building blocks or immunological agents [1,
2, 3, 4, 5, 6, 7]. In humans, the amyloid formation is frequently associated with
neurodegenerative diseases and abnormal metabolic conditions [8, 9, 10, 11].
The structural studies of amyloid aggregates were considered to be difficult
until recently, since being aggregates, they cannot be crystallized and measured
by X-ray diffractometry. With the recent developments of solid-state NMR and
cryo-electron microscopy, dozens of amyloid structures were deposited in the
Protein Data Bank (PDB) [12, 13] in the past several years.
With the more than 100 amyloid structures among the PDB’s 156 thousand
entries, it is now possible to define structural characteristics, which well-describe
amyloid structures. One good approach was made by [13], where the authors,
with the application of a combination of textual search and specific geometric
conditions, successfully retrieved the known amyloid structures from the PDB.
In a recent work of ours [14], we have defined a geometric set of constraints,
by which we selected all the amyloid molecules, found by the method of [13],
plus numerous globular proteins, with partial amyloid-like substructures. We
emphasize that we were using geometric constraints for the β-sheet regions in
the coordinate sections of the PDB files, without any textual search in the an-
notation section of those files. Since the annotation sections of PDB files are
known to be less reliable than the coordinate sections, this technique increases
the reliability of our results, and, additionally, helps in devising the proper defi-
nition of the amyloid-like structures. The resulting selection of the PDB entries,
called the PDB Amyloid list, is available as an automatically and regularly up-
dated list of PDB entries, at the site http://pitgroup.org/amyloid/. Since,
on the average, around 30 new PDB entries are deposited every day, the “auto-
matic update” feature is clearly necessary for this service. The PDB Amyloid
list contains more than 640 entries today.
The geometric constraints, applied in [14], are as follows:
(i) First, parallel β-sheet segments are identified. The parallel segments need
to be on separate polypeptide chains, their distance needs to be between
2 and 15 A˚, and the standard deviation of their distance needs to be less
than 1.5 A˚.
(ii) Second, the large curvature parallel segments are excluded;
(iii) Third, the parallel segments need to cover at least the one-seventh of the
length of the whole chain.
For a more detailed mathematical description of the constraints above, we
refer to the original article [14].
We note that the requirement of considering only segments on separate
polypeptide chains efficiently excludes hairpin and β-barrel structures, and also
partial molecular structures, labeled as “amyloids”, but lacking the repeated,
parallel β-sheets in the PDB-deposited files.
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Prefixes
The more than 640 PDB entries, available at http://pitgroup.org/
amyloid/, yield a rich set of amyloid-related molecular structures. The list
of the globular proteins (i.e., not the misfolded, aggregated amyloid structures)
have a special feature: These molecules remained soluble, but they have partial
sub-structures, satisfying the conditions (i), (ii) and (iii) above. We believe that
the sequence-borders of the β-sheets in these structures have specific roles in the
prevention of the transitions to amyloid state: in the globular proteins, these
border-regions may prevent or regulate the formation of aggregated amyloid
structures from the protein.
In the present contribution, we consider the prefixes of the parallel β-sheets
of the entries of the PDB Amyloid list http://pitgroup.org/amyloid/. These
prefixes are the starting subsections, where the order of the residues is the default
N-terminus through C-terminus.
Here we identify the most frequently found prefixes in the PDB Amyloid list,
and then we search for them in the complete Protein Data Bank. We identify
numerous interesting hits, which have proven connections to amyloid forma-
tion. We stress that the hits, analyzed below, are found by sequence-searches in
the whole PDB, without using any additional structural constraints, where the
sequences we searched for were the prefixes, identified in the PDB Amyloid list.
Methods
First, the defining parallel β-sheets, satisfying the conditions (i), (ii) and (iii)
in the Introduction, of the PDB Amyloid list http://pitgroup.org/amyloid/,
were identified.
Next, we collected the length-5 prefixes of the form XXYYY, where the
first three residues of the parallel β-sheet are YYY, and the last two residues,
preceding the parallel section of the β-sheet, are XX.
Figure 1 depicts the GLN-LYS-LEU-VAL-PHE (QKLVF) prefix from the
amyloid structure of the PDB entry 2MPZ.
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Figure 1: PDB entry 2MPZ, depicted with PyMol. Yellow color denotes β-sheets. The QKLVF
prefix, where QK is green (it is not a part of the parallel β-sheet) and LVF is yellow (i.e., LVF
are the first three residues of the parallel β-segment), is emphasized at the right bottom of
the figure, while its corresponding sequence at the top center.
Next, we have counted the number of appearances of the prefixes and
the suffixes in the parallel β-sheet segments in the PDB Amyloid list http:
//pitgroup.org/amyloid/. Note that one PDB entry may contain more than
one identical prefixes (like in the case of PDB entry 2MPZ, shown in Figure 1).
Therefore, the prefix and suffix counts contain multiplicities of two types: (i)
multiple appearances in the very same PDB entry, or (ii) multiple appearances
in different – and possibly homologous – PDB entries. Instead of introducing an
unnecessarily complex homogeneity-corrected counting method for the prefix-
and suffix appearances in the PDB Amyloid list, we just count their raw, uncor-
rected number of appearances. Since the inclusion or exclusion of the protein
structures in the PDB mostly relate to the interest of researchers depositing the
structures, and do not carry a statistical or biological meaning. Moreover, we
do not count the appearances in the whole PDB, just in the amyloid-like sublist
of PDB Amyloid. These counts (either corrected or uncorrected) can only be
used informally, and do not show the frequency of these subsequences in the
protein structures in Nature.
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Discussion and results
In what follows, we consider the PDB Amyloid list and note if the prefix
appears in structures, described by the application of NMR spectroscopy (both
solid and liquid phase), or by X-ray diffractometry.
The QKLVF Prefix
The QKLVF prefix (i.e., GLN, LYS, LEU, VAL, PHE) appears 77 times in
the NMR-identified members of the PDB Amyloid list, in the following PDB-
structures: 2LMN, 2LMO, 2LMP, 2LMQ, 2LNQ, 2MPZ. The 2MPZ structure
is depicted in Figure 1. We are interested in the appearances of the QKLVF
subsequence in the whole PDB, and we intend to identify the protein structures,
which have the proven potential to turn to amyloids.
Among the numerous β-amyloid hits, which are not reviewed here, several
interesting appearances of the QKLVF subsequence in globular proteins are in
the T-cell receptors (TCR), bound with the major histocompatibility complexes
MHC-1 and MHC-2, in the PDB entries 4P5T, 4OZF, 3QIU, 3QIW, 1BD2,
2IAN, 2IAM, 2IAL, 4WW1, 4WW2, 5XOT. Very interestingly, the misfolded
MHC molecules in activated T-cells have a signaling function [15]. Additionally,
the MHC molecule is known to misfold in several cases when in complex with
TCR, and then it is is degraded by housekeeping enzymes [? ]. These articles
show that the normally globular MHC molecules are known to misfold if in
complex with the TCR molecule, containing the QKLVF subsequence.
The GEYFT Prefix
The GEYFT prefix (GLY, GLU, TYR, PHE, THR) appears 48 times in the
NMR-identified members of the PDB Amyloid list, in the PDB entries 1OLG,
1SAE, 1SAF, 1SAK, 1SAL, 3SAK. These are non-amyloid structures. One of
them, 1OLG is depicted in Figure 2.
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Figure 2: PDB entry 1OLG, depicted with PyMol. Yellow color denotes β-sheets. The
GEYFT prefix, where GE are green (it is not a part of the parallel β-sheet) and YFT are
yellow (i.e., YFT are the first three residues of the parallel β-segment), is emphasized at the
left middle section of the figure, while its corresponding sequence at the lower left corner.
Numerous GEYFT appearances in the PDB Amyloid list and also in the
whole PDB are in p53 structures. p53 is a major tumor suppressor protein,
whose gene is mutated in half of the human cancers [16, 17, 18], and both its
mutational deficiency in humans and the knock-out of its gene in mice imply
early on-set cancers [19, 20]. It is very surprising that p53 mutations have
a tendency of prion-like, contagious amyloid transitions: it is found that the
amyloid-like aggregation plays a role in the loss of the p53 function in several
organisms and cell types [21, 22, 23].
We note that identifying non-amyloid p53 structures in the PDB Amyloid
list shows the power of the methods by which the PDB Amyloid list was created
[14]: p53, an important non-amyloid structure with amyloidogenic properties is
found in the list. We also note that numerous appearances of the GEYFT
sequence in the whole PDB are also found in the p53 proteins.
Many GEYFT prefixes in the whole PDB are found in Mycobacterium (either
tuberculosis or smegmatis) RNA polymerase transcription initialization com-
plexes (e.g., 6DVC, 6JCX, 6JCY, 5ZX2). While it is not documented that these
initialization complexes form amyloids, other bacterial transcriptional regulators
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do form amyloids. The Bacillus subtilis HeID, an RNA polymerase interacting
helicase forms amyloids, as it was reported recently in [24]. Another finding
that a mycobacterial global transcriptional factor, CarD, also forms amyloids,
both in vivo and in vitro [25]. Therefore, it would not be surprising if the
GEYFT-containing mycobacterial RNA polymerase transcription initialization
complexes also formed amyloid fibrils.
The HQKLV Prefix
The HQKLV prefix (HIS, GLN, LYS, LEU, VAL) appears 25 times in the
NMR-identified members of the PDB Amyloid list, in the PDB entries 2LMN,
2LMO, 2LMP, 2LMQ; these are all β-amyloid fibrils. If we search for the
HQKLV subsequence in the whole PDB, we find numerous amyloid structures
and some human amphiphysins: human amphiphysin isoform 1 (PDB codes
3SOG, 4ATM), and human BIN1/amphiphysin II (2FIC). Interestingly, the
HQKLV subsequence appears in these pure α-helix BIN1-structures as the part
of the helix (Figure 3).
Figure 3: PDB entry 2FIC: the BAR domain of the human Bin1/amphiphysin II, depicted
with PyMol. The red colored sections of the α-helices correspond to the HQKLV subsequence.
BIN1 is not known to form amyloid-fibrils, but it is well-known to relate to
late-onset Alzheimer’s-disease: its gene is the second most important risk locus
for Alzheimer’s disease (after APOE: apolipoprotein E) [26], it is related to
increased susceptibility for Alzheimer’s disease [? ]. More recently, it was shown
that BIN1 regulates BACE trafficking and β-amyloid production. Therefore, we
may conjecture that the HQKLV subsequence plays a role in amyloid-formation,
even if it is in an α-helix in BIN1 structures (Figure 3).
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The GGERA Prefix
The GGERA prefix (GLY. GLY. GLU, ARG, ALA) appears 106 times in
the X-ray crystallography-identified members of the PDB Amyloid list, in the
PDB entries 1DW9, 1DWK, 2IU7, 2IV1, 2IVQ, 4Y42; these are all bacterial
cyanases. If we search for the GGERA subsequence in the whole PDB, the
most interesting hit is the structure 1TCP: this is a tick anticoagulant peptide
(TAP). The position of the GGERA subsequence is depicted in Figure 4.
Figure 4: PDB entry 1TCP: the tick anticoagulant peptide (TAP), depicted with PyMol. The
blue-colored section correspond to the GGERA prefix: GG preceeding the first three residues,
ERA, in the β-sheet.
The β-sheet prefixes, listed above, were all related to prion- or amyloid-
formation. Here, GGERA is found in an anti-coagulant molecule: the tick
anti-coagulant peptide. Therefore, the GGERA subsequence is
• the prefix of the parallel β-sheet sections of several soluble proteins
(cyanases) from the PDB Amyloid list, therefore the β-sheet, which starts
with the GGERA sequence, is similar to those in the amyloid-structures,
by satisfying properties (i), (ii) and (iii), listed in the Introduction;
• but the cyanases 1DW9, 1DWK, 2IU7, 2IV1, 2IVQ, 4Y42 are all soluble
proteins.
Consequently, since GGERA also appears in the anti-coagulant 1TCP, it may
have anti-amyloidogenic properties.
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Conclusions
By searching for the prefixes of the parallel β-sheet sections of the entries in
the PDB Amyloid list in http://pitgroup.org/amyloid/, we were able to find
numerous proteins in the whole PDB, from which only very recently were shown
that they relate to the amyloid-formation. We conjecture that the prefixes listed
may have structural roles in these amyloidogenic properties.
Data availability
The automatically updated PDB Amyloid web page is available at http:
//pitgroup.org/amyloid/. The list of the PDB codes of the PDB Amyloid can
be viewed and downloaded at http://pitgroup.org/apps/amyloid/amyloid_
list.
Acknowledgments
KT and VG were partially funded by the VEKOP-2.3.2-16-2017-00014 and
the EFOP-3.6.3-VEKOP-16-2017-00002 programs, supported by the European
Union and the State of Hungary. VG was partially funded by the NKFI-126472
and the NKFI-127909 grants of the National Research, Development and Inno-
vation Office of Hungary.
Conflict of Interest: The authors declare no conflicts of interest.
Author contributions:
VG initiated the study, analyzed the results and wrote the paper. KT iden-
tified the parallel β-sheet segments in the spatial protein structures, and the
prefixes in those β-sheets, satisfying the constraints, and described their ap-
pearances.
References
[1] Martijn FBG Gebbink, Dennis Claessen, Barend Bouma, Lubbert Di-
jkhuizen, and Han AB Wo¨sten. Amyloids - a functional coat for microor-
ganisms. Nature Reviews Microbiology, 3(4):333–341, 2005.
[2] Luz P Blanco, Margery L Evans, Daniel R Smith, Matthew P Badtke,
and Matthew R Chapman. Diversity, biogenesis and function of microbial
amyloids. Trends in Microbiology, 20(2):66–73, 2012.
[3] Vassiliki A Iconomidou and Stavros J Hamodrakas. Natural protective
amyloids. Current Protein and Peptide Science, 9(3):291–309, 2008.
9
[4] Patrizia Falabella, Lea Riviello, Mariarosa Pascale, Ilaria Di Lelio, Gianluca
Tettamanti, Annalisa Grimaldi, Carla Iannone, Maria Monti, Piero Pucci,
Antonio Mario Tamburro, et al. Functional amyloids in insect immune
response. Insect Biochemistry and Molecular Biology, 42(3):203–211, 2012.
[5] Samir K Maji, Marilyn H Perrin, Michael R Sawaya, Sebastian Jessberger,
Krishna Vadodaria, Robert A Rissman, Praful S Singru, K Peter R Nilsson,
Rozalyn Simon, David Schubert, et al. Functional amyloids as natural
storage of peptide hormones in pituitary secretory granules. Science, 325
(5938):328–332, 2009.
[6] Nora Taricska, Daniel Horvath, Dora K Menyhard, Hanna Akontz-Kiss,
Masahiro Noji, Masatomo So, Yuji Goto, Toshimichi Fujiwara, and Andras
Perczel. The route from the folded to the amyloid state: Exploring the
potential energy surface of a drug-like miniprotein. Chemistry (Weinheim
an der Bergstrasse, Germany), January 2020. ISSN 1521-3765. doi: 10.
1002/chem.201905181.
[7] Daniel Horvath, Dora K Menyhard, and Andras Perczel. Protein aggre-
gation in a nutshell: The splendid molecular architecture of the dreaded
amyloid fibrils. Current protein & peptide science, 20:1077–1088, 2019.
ISSN 1875-5550. doi: 10.2174/1389203720666190925102832.
[8] Alois Alzheimer. Uber eine eigenartige erkrankung der hirnrinde. Allge-
meine Zeitschrife Psychiatrie, 64:146–148, 1907.
[9] Jeffrey W. Prescott, Arnaud Guidon, P Murali Doraiswamy, Kingshuk Roy
Choudhury, Chunlei Liu, Jeffrey Petrella, and For the Alzheimer’s Disease
Neuroimaging Initiative . The Alzheimer Structural Connectome: Changes
in cortical network topology with increased amyloid plaque burden. Radi-
ology, page 132593, May 2014.
[10] Buyong Ma and Ruth Nussinov. Stabilities and conformations of
Alzheimer’s beta -amyloid peptide oligomers (Abeta 16-22, Abeta 16-35,
and Abeta 10-35): Sequence effects. Proc Natl Acad Sci U S A, 99
(22):14126–14131, Oct 2002. doi: 10.1073/pnas.212206899. URL http:
//dx.doi.org/10.1073/pnas.212206899.
[11] Jie Zheng, Hyunbum Jang, Buyong Ma, Chung-Jun Tsai, and Ruth Nussi-
nov. Modeling the alzheimer abeta17-42 fibril architecture: tight inter-
molecular sheet-sheet association and intramolecular hydrated cavities.
Biophys J, 93(9):3046–3057, Nov 2007. doi: 10.1529/biophysj.107.110700.
URL http://dx.doi.org/10.1529/biophysj.107.110700.
[12] H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig,
I.N. Shindyalov, and P.E. Bourne. The Protein Data Bank. Nucleic Acids
Research, 28:235–242, 2000.
10
[13] Ivana Stankovic´, Michael B Hall, and Snezˇana D Zaric´. Construction of
amyloid PDB files database. The IPSI BgD Transactions on Internet Re-
search, 13(1):47–51, 2017. ISSN ISSN 1820-4503).
[14] Kristo´f Taka´cs, Ba´lint Varga, and Vince Grolmusz. PDB Amyloid: an
extended live amyloid structure list from the PDB. FEBS Open Bio, 9(1):
185–190, 2019.
[15] Susana G Santos, Simon J Powis, and Fernando A Arosa. Misfold-
ing of major histocompatibility complex class i molecules in activated t
cells allows cis-interactions with receptors and signaling molecules and
is associated with tyrosine phosphorylation. The Journal of biologi-
cal chemistry, 279:53062–53070, December 2004. ISSN 0021-9258. doi:
10.1074/jbc.M408794200.
[16] B Vogelstein, D Lane, and A J Levine. Surfing the p53 network. Nature,
408:307–310, November 2000. ISSN 0028-0836. doi: 10.1038/35042675.
[17] Ana I Robles and Curtis C Harris. Clinical outcomes and correlates of
tp53 mutations and cancer. Cold Spring Harbor perspectives in biology, 2:
a001016, March 2010. ISSN 1943-0264. doi: 10.1101/cshperspect.a001016.
[18] Magali Olivier, Monica Hollstein, and Pierre Hainaut. Tp53 mutations
in human cancers: origins, consequences, and clinical use. Cold Spring
Harbor perspectives in biology, 2:a001008, January 2010. ISSN 1943-0264.
doi: 10.1101/cshperspect.a001008.
[19] D Malkin, F P Li, L C Strong, J F Fraumeni, C E Nelson, D H Kim,
J Kassel, M A Gryka, F Z Bischoff, and M A Tainsky. Germ line p53
mutations in a familial syndrome of breast cancer, sarcomas, and other
neoplasms. Science (New York, N.Y.), 250:1233–1238, November 1990.
ISSN 0036-8075. doi: 10.1126/science.1978757.
[20] L A Donehower, M Harvey, B L Slagle, M J McArthur, C A Montgomery,
J S Butel, and A Bradley. Mice deficient for p53 are developmentally normal
but susceptible to spontaneous tumours. Nature, 356:215–221, March 1992.
ISSN 0028-0836. doi: 10.1038/356215a0.
[21] Shinjinee Sengupta, Samir K Maji, and Santanu K Ghosh. Evidence
of a prion-like transmission of p53 amyloid in saccharomyces cerevisiae.
Molecular and cellular biology, 37, September 2017. ISSN 1098-5549. doi:
10.1128/MCB.00118-17.
[22] Jerson L Silva, Claudia V De Moura Gallo, Danielly C F Costa, and Lu-
ciana P Rangel. Prion-like aggregation of mutant p53 in cancer. Trends
in biochemical sciences, 39:260–267, June 2014. ISSN 0968-0004. doi:
10.1016/j.tibs.2014.04.001.
11
[23] Jerson L Silva, Elio A Cino, Iaci N Soares, Vitor F Ferreira, and Guilherme
A P de Oliveira. Targeting the prion-like aggregation of mutant p53 to
combat cancer. Accounts of chemical research, 51:181–190, January 2018.
ISSN 1520-4898. doi: 10.1021/acs.accounts.7b00473.
[24] Gundeep Kaur, Srajan Kapoor, and Krishan G Thakur. Bacillus sub-
tilis held, an rna polymerase interacting helicase, forms amyloid-like fib-
rils. Frontiers in Microbiology, 9:1934, 2018. ISSN 1664-302X. doi:
10.3389/fmicb.2018.01934.
[25] Gundeep Kaur, Soni Kaundal, Srajan Kapoor, Jonathan M Grimes,
Juha T Huiskonen, and Krishan Gopal Thakur. Mycobacterium tuber-
culosis card, an essential global transcriptional regulator forms amyloid-
like fibrils. Scientific Reports, 8:10124, July 2018. ISSN 2045-2322. doi:
10.1038/s41598-018-28290-4.
[26] Meng-Shan Tan, Jin-Tai Yu, and Lan Tan. Bridging integrator 1 (BIN1):
form, function, and Alzheimer’s disease. Trends in molecular medicine, 19:
594–603, October 2013. ISSN 1471-499X. doi: 10.1016/j.molmed.2013.06.
004.
12
